Crossmark

Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement

Crossref DOI link: https://doi.org/10.1186/s12872-019-1021-7

Published Online: 2019-02-26

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Berntorp, Karolina https://orcid.org/0000-0001-8966-2112
Koul, Sasha

Nozohoor, Shahab

Harnek, Jan

Bjursten, Henrik

Götberg, Matthias
Funding

Funding for this research was provided by:

Skåne University Hospital, Sweden

Westerströms stiftelse
License Information

Text and Data Mining valid from 2019-02-26
More Information

Article History

Received: 24 October 2017

Accepted: 15 February 2019

First Online: 26 February 2019

Ethics approval and consent to participate

: No specific consent for participation in the registry was needed since the data collected was identical to already available data in SWEDEHEART, which is a national quality registry and does not require consent. The data from the SWEDEHEART and the pacemaker registry is not publically available and therefore required ethics approval which was approved by Lund University ethics committee (LU2009/87), Lund, Sweden. The study as a whole was also approved by Lund University ethics committee (LU2009/87), Lund, Sweden, including administrative permission for obtaining and collecting data as well as medical records.

: Not applicable.

: HB, MG, JH has received consulting fees from Boston Scientific corporation to serve as proctors for the Lotus Valve.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.